MTMuskan Turesh

Muskan Turesh

*This is an algorithmically generated author record based on publicly available information.

Muskan Turesh has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness of thiazide diuretics in patients with hypertension: a systematic review and meta-analysis

    by Taimoor Ashraf, Fnu Chandni, Fnu Nancy, Nisha Devi, Deepa Bai, Ramsha Waseem, Maheen Jabbar, Muskan Turesh, Shah Dev, Rabia Bint I Zafar, et al.

    Background: Thiazide diuretics are commonly prescribed for the treatment of hypertension (HTN). However, the comparative efficacy and safety of hydrochlorothiazide (HCTZ) versus chlorthalidone (CTD) in managing patients with HTN remain unclear. Materials and Methods: A comprehensive literature search was performed using two electronic databases, MEDLINE and Cochrane, from their inception through November 2024. The aim was to identify randomized controlled trials or observational double-arm studies assessing the effects of HCTZ versus CTD on cardiovascular outcomes and safety in patients with HTN. Outcomes were reported as hazard ratios (HRs) with 95% confidence intervals (CIs), and analyses were conducted using a random effects model. A P -value of <0.05 was considered statistically significant. Results: Of the 409 articles identified in the initial search, six relevant studies were included in the final analysis. No significant differences were observed between the HCTZ and CTD arms for cardiovascular outcomes, including major adverse cardiovascular events, myocardial infarction, stroke, hospitalization for heart failure, and angina. However, patients receiving CTD experienced significantly higher rates of hypokalemia and hyponatremia compared to those on HCTZ. The risk of acute kidney injury did not differ significantly between the two groups. Conclusion: HCTZ and CTD showed comparable efficacy in terms of cardiovascular outcomes. Nevertheless, HCTZ appeared to have a safer profile, with a lower incidence of electrolyte imbalances, such as hypokalemia and hyponatremia, compared to CTD.


  • Open Access

    Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs

    by Omar Abunada, Farhad Hassan, Naresh Kumar, Sunil Kumar, Irfan Majeed, Kantesh Batra, Dheeraj Kumar, Deepika Deepika, Muskan Turesh, Taimoor Ashraf, et al.

    Introduction: Effective treatment approaches are required for type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) because these two diseases pose a big health issue for humans. Various medications, but with limitations in their efficacy, are available for the treatment of the above-mentioned diseases, but a drug, empagliflozin, a sodium–glucose cotransporter-2 inhibitor, has shown promising benefits for patients with T2DM and CVD, highlighting the need for a thorough review of its efficacy and safety. Methods: We searched online databases till 30 June 2024, and a total of 15 trials involving 8296 participants were included in this study. Evaluating the changes in HbA1c was a main concern of our study, while weight-related metrics [such as body weight and Body Mass Index (BMI)], cardiovascular indicators [like systolic blood pressure (SBP), diastolic blood pressure (DBP), changes in left ventricular ejection fraction %, and heart rate], and various laboratory values [including fasting plasma glucose (FPG), C-reactive protein (CRP), hematocrit, estimated glomerular filtration rate] were considered as secondary assessments. Results: Our study concluded that empagliflozin significantly reduced HbA1c levels [standardized mean difference (SMD) = −0.62, 95% CI = −0.95 to −0.30, I 2 = 85%, P = 0.0001], indicating improved glycemic control. Additionally, a reduction in body weight was also noted (SMD = −2.32, 95% CI = −3.42 to −1.21, I 2 = 54%, P < 0.0001). The drug also demonstrated favorable outcomes for secondary endpoints. Meta-regression and subgroup analyses provided insights into the variability of treatment effects across different populations. Conclusions: The efficacy of empagliflozin in managing T2DM and CVD is evaluated by this pooled analysis, highlighting great improvement in glycemic control and weight reduction. Further research is needed for empagliflozin’s long-term safety and efficacy across populations.


  • Open Access

    Nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: a systematic review and meta-analysis

    by Ramsha Waseem, Ajay Kumar, Simran Kumari, Sagar Kumar, Deepa Bai, Ganesh Kumar, Maheen Jabbar, Taimoor Ashraf, Fnu Nancy, Bibi Mariam, et al.

    Background: Contrast-induced nephropathy (CIN) remains a significant complication in patients undergoing coronary angiography (CAG) and percutaneous coronary intervention (PCI). Methods: A comprehensive literature search was conducted across PubMed, MEDLINE, Embase, Google Scholar, and Web of Science up to May 2024 to identify randomized controlled trials (RCTs) evaluating the efficacy and safety of nicorandil in patients undergoing CAG or PCI. The primary outcome was CIN incidence, while secondary outcomes included, changes in serum creatinine, serum cystatin C, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). Risk ratios (RRs) and standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was assessed using the I2 statistic. Results: Eleven RCTs and one prospective cohort study involving 2910 patients were included. Nicorandil administration was associated with a significant reduction in CIN incidence (RR: 0.40 [0.31–0.52], P < 0.00001), with both oral (RR: 0.35 [0.25–0.48], P < 0.00001) and intravenous formulations (RR: 0.52 [0.30–0.92], P = 0.02) demonstrating efficacy (p-interaction = 0.22). Patients receiving nicorandil exhibited significantly lower serum creatinine levels at 48 hours (SMD: −0.34 [–0.52, −0.16], P = 0.0002) and 72 hours (SMD: −0.24 [–0.40, −0.08], P = 0.003) post-procedure. Serum cystatin C was also significantly reduced at 48 hours (SMD: −0.48 [–0.81, −0.15], P = 0.004). However, nicorandil did not produce a significant change in eGFR at 24 hours (SMD: 0.17 [–0.07, 0.41], P = 0.17), 48 hours (SMD: 0.13 [–0.10, 0.37], P = 0.26), or 72 hours (SMD: 0.19 [–0.07, 0.45], P = 0.36). Conclusion: Nicorandil administration reduces CIN incidence and improves renal biomarker profiles in patients undergoing CAG and PCI. Further large-scale trials are necessary to validate its renoprotective properties.


  • Open Access

    Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights

    by Taimoor Ashraf, Akshy Kumar, Aniket Tara, Naila Memon, Areej Muhammad, Muskan Turesh, Shah Dev, Noor Muhammad, Vikash Kumar, Tooba Hussain, et al.

    Introduction: Type 2 diabetes mellitus (T2DM) is a progressive condition often necessitating insulin therapy for sustained glycemic control, yet adherence to daily injections remains a significant challenge. While insulin glargine is effective, reducing injection frequency may improve compliance and outcomes. This study evaluates the efficacy and safety of once-weekly insulin icodec compared to once-daily insulin glargine U100. Methods: This systematic review and meta-analysis followed Cochrane and PRISMA guidelines. A comprehensive search across multiple databases identified randomized controlled trials (RCTs) comparing once-weekly insulin icodec with once-daily insulin glargine U100 in adults with T2DM. Eligible studies included adult participants and reported glycemic or safety outcomes. Data synthesis was performed using a random-effects model, with heterogeneity assessed via the I2 statistic. Results: Five RCTs comprising 2,019 participants met the inclusion criteria. Insulin icodec significantly reduced glycated hemoglobin (MD: −0.12; 95% CI: −0.20, −0.04; P = 0.003) and increased time in range (TIR; MD: 4.23; 95% CI: 2.20, 6.26; P < 0.0001) compared to insulin glargine. A modest increase in body weight was observed with insulin icodec, while safety profiles, including hypoglycemia rates and adverse events, were comparable between treatments. Conclusion: Insulin icodec provides a safe and effective alternative to once-daily insulin glargine for T2DM management, offering similar glycemic control with a once-weekly dosing regimen. The reduced injection burden may enhance adherence and treatment satisfaction, potentially improving long-term disease outcomes.


  • Open Access

    Vitamin D supplementation among postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis

    by Taimoor Ashraf, Muhammad Abdul Moiz, Ganesh Kumar, Akshay Kumar, Vishal Kumar, Vivek Anand, Fnu Sunita, Naresh Kumar Ladhwani, Tooba Hussain, Shah Dev, et al.

    Aims: To determine whether vitamin D supplementation reduces the incidence of postoperative atrial fibrillation (POAF) in patients undergoing coronary artery bypass grafting (CABG). Methods and Results: PubMed and Cochrane Central Register of Controlled Trials were systematically searched from inception through May 2023 for randomized controlled trials (RCTs) assessing the effectiveness of Vitamin D in preventing atrial fibrillation among postoperative patients after CABG. The primary outcome extracted was the incidence of atrial fibrillation after Vitamin D in CABG patients. Secondary outcome included the length of hospital stay. Data were pooled using a random-effect model. A total of 4 RCTs, including 694 patients, were included in the final analysis. The results showed that Vitamin D supplementation significantly reduced the incidence of POAF in CABG patients (RR: 0.55; 95% CI: 0.40 to 0.76; P = 0.0003; I 2 = 1%). However, administration of Vitamin D did not lead to significant reduction in the length of hospital stay (WMD: − 0.14; 95% CI: − 0.82 to 0.53; P = 0.68; I 2 = 34%). Conclusion: Our updated pooled analysis concludes that Vitamin D reduces the incidence of POAF in CABG patients. Future large-scale studies should focus on more diverse patient populations and explore a broader range of outcomes to better understand the full impact of Vitamin D supplementation in this context.